Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukemia.

M J Mauro1, B J Druker

  • 1Leukemia Program, Oregon Health Sciences University, Portland, Oregon, USA.

Current Opinion in Oncology
|January 10, 2001
PubMed
Summary

Chronic myelogenous leukemia (CML) is a blood stem cell disorder. A new targeted therapy, STI571, offers hope for improved treatment options beyond traditional therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knight Scholars Program: A Tiered Three-Year Mentored Training Program for Urban and Rural High School High School Students Increases Interest and Self-Efficacy in Interprofessional Cancer Research.

Journal of STEM outreach·2023
Same author

Recurrent cyclin D2 mutations in myeloid neoplasms.

Leukemia·2017
Same author

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.

Leukemia·2016
Same author

Age-related mutations and chronic myelomonocytic leukemia.

Leukemia·2015
Same author

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Leukemia·2015
Same author

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.

Leukemia·2015

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myelogenous leukemia (CML) is a stem cell disorder caused by the (9:22) translocation, leading to an overactive bcr-abl tyrosine kinase.
  • CML is clinically defined by myeloid proliferation and typically progresses to acute leukemia.
  • Current standard treatments include interferon and stem cell transplantation, with the latter offering curative potential.

Purpose of the Study:

  • To introduce STI571, a novel bcr-abl tyrosine kinase inhibitor, as a targeted therapy for CML.
  • To highlight the potential of molecular monitoring in CML patient treatment.
  • To present STI571 as a new therapeutic option for CML.

Main Methods:

  • Rational drug development leading to the identification of STI571.
  • Focus on targeted therapy by inhibiting the bcr-abl tyrosine kinase.
  • Integration of molecular methods for monitoring treatment response.

Main Results:

  • STI571 has emerged as a targeted therapy for CML.
  • The drug specifically inhibits the bcr-abl tyrosine kinase.
  • This targeted approach offers new hope for CML patients.

Conclusions:

  • STI571 represents a significant advancement in CML treatment.
  • Targeted inhibition of bcr-abl tyrosine kinase provides a new therapeutic strategy.
  • Improved molecular monitoring will be crucial as CML therapies evolve.

Related Experiment Videos